Bipolar Disorder
Conditions
Brief summary
This study will enroll 30 adolescents with bipolar disorder (BD) who are suffering from symptoms of depression despite already taking a traditional mood-stabilizing medication. Curcumin will be added to their current medications for 8 weeks. During these 8 weeks, their mood symptoms will be assessed regularly. Height, weight, and blood pressure will also be measured repeatedly. Blood tests will be completed before treatment, after 4 weeks of treatment, and at the end of the study. Blood tests will allow us to determine whether changes in inflammation and oxidative stress explain curcumin's effect on mood. Finally, we will use sophisticated technology to measure blood vessel functioning. We have three main predictions: 1. Curcumin will improve mood symptoms without causing physical problems; 2. Curcumin will reduce inflammation and oxidative stress, and these reductions will be linked to improvements in mood; 3. Curcumin will improve blood vessel functioning, and these improvements will be linked to improved inflammation and oxidative stress.
Interventions
DRUGCurcumin
Sponsors
The Depressive and Bipolar Disorder Alternative Treatment Foundation
Sunnybrook Health Sciences Centre
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
13 Years to 19 Years
Healthy volunteers
No
Inclusion criteria
* English speaking * all races and ethnicities * bipolar disorder I or II * currently treated with lithium, divalproex, lamotrigine, and/or second generation antipsychotic * doses stable for greater than or equal to 4 weeks * current CGI BP score of moderate or greater * current CDRS-R severity of greater than or equal to 35
Exclusion criteria
* If female, pregnant or sexually active without reliable contraception * significant suicidal ideations (as determined by clinical interview or CDRS-R \> 3) and/or any suicidal intent, even if fleeting or non-recurrent, in the preceding 2 weeks * substance dependence within the past 2 months * daily antidepressant, glucocorticoid, nonsteroidal anti-inflammatory, anti-platelet, anti-coagulant, antacid, or oral hypoglycemic medication or insulin; high-dose antioxidant vitamin supplements or other natural health products that may function as an antidepressant within 30 days of baseline * IQ\<80 or autistic disorder * full threshold mania and/or YMRS \> 20 and/or psychosis * hypersensitivity to curcumin/turmeric, gelatin * dietary consumption of curcumin/turmeric \> 3 times/week * clinically significant or unstable medical disorder; known gallstones and/or bile duct obstruction, stomach ulcers, excessive stomach acid/heartburn/gastroesophageal reflux disease (GERD); or clinically significant baseline laboratory abnormalities; or ALT and /or AST above the upper limit of normal on repeat examination at baseline * severe depression (CDRS-R \> 98) and/or severely ill (CGI BP \>5)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Children's Depression Rating Scale - Revise (CDRS-R) | Change from baseline to endpoint (assessed at weeks 0, 2, 4, 6, 8) | Measures mood symptom severity. Response is defined as greater than or equal to 50% reduction in CDRS-R score. |
| Oxidative Stress Markers | Change from baseline to endpoint (measured at weeks 0, 4, 8) | Obtained through blood work |
| Pro-Inflammatory Markers | Change from baseline to endpoint (measured at weeks 0, 4, 8) | Obtained through blood work |
| Endothelial Function | Change from baseline to endpoint (measured at weeks 0, 4, 8) | Will be assessed via RH-PAT using the EndoPAT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Screen for Child Anxiety Related Emotional Disorders (SCARED) | Change from baseline to endpoint (assessed at weeks 0, 2, 4, 6, 8) | Anxiety self-report |
| Weight Gain | Change from baseline to endpoint (measured at 0, 4, 8) | Significant weight gain is greater than or equal to 7% of baseline weight |
| Clinical Global Impression - Bipolar Disorder Version (CGI BP) | Change from baseline to endpoint (assessed at weeks 0, 2, 4, 6, 8) | Measures overall illness severity. Remission is defined as an improvement score of 1 or 2. |
| Side Effects for Children and Adolescents (SEFCA) | Change from baseline to endpoint (assessed at weeks 0, 4, 6, 8) | SEFCA is a questionnaire that assesses side effects. We anticipate that no major side-effects will have a prevalence of greater than 20%. |
| Blood Pressure | Change from baseline to endpoint (measured at 0, 4, 8) | — |
| KSADS Depression Section (KDRS) | Change from baseline to endpoint (assessed at weeks 0, 2, 4, 6, 8) | Measures mood symptoms severity |
| KSADS Mania Rating Scale (KMRS) | Change from baseline to endpoint (assessed at weeks 0, 2, 4, 6, 8) | Measures symptoms severity |
| Young Mania Rating Scale (YMRS) | Change from baseline to endpoint (assessed at weeks 0, 2, 4, 6, 8) | Measures symptom severity |
Countries
Canada
Outcome results
None listed